Dr Reddys Laboratories fell 2.36% to Rs 2,463 at 14:25 IST on BSE after consolidated net profit surged 69.41% to Rs 690.25 crore on 17.14% increase in total income to Rs 3421.12 crore in Q2 September 2013 over Q2 September 2012.
The result was announced during trading hours today, 31 October 2013.
Meanwhile, the BSE Sensex was up 32.19 points, or 0.15%, to 21,066.16.
On BSE, 66,000 shares were traded in the counter compared with average volume of 22,561 shares in the past one quarter.
The stock hit a high of Rs 2,545 so far during the day, which is also a record high for the counter. The stock hit a low of Rs 2,448 so far during the day. The stock hit a 52-week low of Rs 1,711.60 on 16 November 2012.
The stock had underperformed the market over the past one month till 30 October 2013, rising 5.83% compared with the Sensex's 8.54% rise. The scrip had, however, outperformed the market in past one quarter, rising 15.75% as against Sensex's 8.71% rise.
The large-cap company has an equity capital of Rs 85.05 crore. Face value per share is Rs 5.
Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars, differentiated formulations and new chemical entities (NCEs).
Powered by Capital Market - Live News
